We can’t show the full text here under this license. Use the link below to read it at the source.
A randomised, double‐blind study in adults with major depressive disorder with an inadequate response to a single course of selective serotonin reuptake inhibitor or serotonin–noradrenaline reuptake inhibitor treatment switched to vortioxetine or agomelatine
Switching to Vortioxetine or Agomelatine in Adults with Major Depression Not Improved by One SSRI or SNRI Treatment: A Randomized, Double-Blind Study
AI simplified
Abstract
Vortioxetine was superior to agomelatine by 2.2 points in reducing depression symptoms after 12 weeks.
- Noninferiority of vortioxetine was established compared to agomelatine for patients with major depressive disorder.
- Significantly higher response and remission rates were observed with vortioxetine at weeks 8 and 12.
- Improvements in anxiety symptoms, overall functioning, health-related quality of life, productivity, and family functioning were noted with vortioxetine starting from week 4.
- Withdrawal due to adverse events was lower in the vortioxetine group (5.9%) compared to the agomelatine group (9.5%).
- Common adverse events for both treatments included nausea, headache, dizziness, and somnolence.
AI simplified
Key numbers
2.2
Mean Difference in Score
Change from baseline to week 8 in total score
69.8%
Response Rate at Week 12
Percentage of patients achieving response based on
5.9%
Withdrawal Rate Due to Adverse Events
Percentage of patients withdrawing from treatment due to adverse events